Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024
Europe biosimilar insulin glargine and lispro market is projected to reach $ 1.9 billion by 2024 owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedentary lifestyle. United Kingdom ranks among the top 5 countries with the highest rate of Type 1 diabetes in children. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of biosimilar insulin glargine and lispro market in the forthcoming years. The insulin analogue retains its glucose lowering property for 24 hours with just one injection. Due to this property, the insulin analogue is preferred for maintaining the basal insulin level throughout the day, thereby aiding the market growth. Growing concern regarding the cost of insulin treatment is surging the demand for biosimilar insulin glargine and lispro that have the potential to reduce diabetes treatment costs, which is anticipated to boost the growth of market in the next 5 years. Moreover, ageing population and changing eating habits are further giving healthy push to Europe biosimilar insulin glargine and lispro market.
On the basis of end users, the biosimilar insulin glargine and lispro market is bifurcated into Type 1 Diabetes and Type 2 Diabetes.Among them, Type 1 Diabetes dominated the market with the largest market share until 2018 and is anticipated to maintain its position during the forecast period as well.
The reason being, Type 1 diabetes is categorized as an autoimmune disease, therefore the body doesn’t produce any insulin.The only way to treat this disorder is getting oneself injected with insulin and getting the blood glucose levels regulated.
Thereby, treatment of Type 1 diabetes generates maximum demand for insulin glargine and lispro in the region.With the higher adoption of sedentary lifestyle, especially in the growing economies people are facing difficulty in controlling Type 2 diabetes.
Therefore, the utilization of biosimilar insulin glargine and lispro to treat Type 2 diabetes is expected to witness some growth during the forecast period.
Some of the players in Europe biosimilar insulin glargine and lispro are Sanofi, Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk, Sandoz-Gan Lee, etc. The key players in the market are using strategies such as launch of new products, mergers and acquisitions to increase their customer base and expand their share in the market.
• To analyze and forecast the market size of Europe biosimilar insulin glargine and lispro market.
• To forecast Europe biosimilar insulin glargine and lispro market based on end user, , and regional distribution.
• To identify drivers and challenges for Europe biosimilar insulin glargine and lispro market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Europe biosimilar insulin glargine and lispro market.
• To conduct the pricing analysis for Europe biosimilar insulin glargine and lispro market.
• To identify and analyze the profile of leading players operating in Europe biosimilar insulin glargine and lispro market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of biosimilar insulin glargine and lispro manufacturers across the region.
Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.
Through this technique, the analyst could include the suppliers which could not be identified due to the limitations of secondary research. The analyst examined the product types, application types and presence of all major biosimilar insulin glargine and lispro manufacturers across the region.
The analyst calculated Europe biosimilar insulin glargine and lispro market size by using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.
Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.
Key Target Audience:
• Biosimilar insulin glargine and lispro manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to biosimilar insulin glargine and lispro market
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers and partners, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
In this report, Europe biosimilar insulin glargine & lispro market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Market, By End User:
o Type 1 Diabetes
o Type 2 Diabetes
• Market, By Country:
o United Kingdom
o The Netherlands
o Rest of Europe
Company Profiles: Detailed analysis of the major companies present in biosimilar insulin glargine & lispro market.
With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:
• Detailed analysis and profiling of additional market players (up to five).
Profit Margin Analysis
• Profit margin analysis in case of direct and indirect sales channel.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi. The global pegfilgrastim biosimilar market is expected to decline from $534.43 million in 2019 to $453.11 million in 2020 at a compound annual growth rate (CAGR) of -15.22%. The decline...
193 pages •
By Global Industry Analysts
• Apr 2021
- Global Biopharmaceutical Bioseparation Systems Market to Reach $12.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceutical Bioseparation Systems estimated at US$7.1 Billion in the year 2020, is projected to reach a revised size of US$12.6 Billion by 2027, growing at aCAGR...
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations,...
In this research service, the Transformational Health team provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in...
“Venetoclax - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diabetic Macular Edema in 7 Major Markets. A detailed picture of the Venetoclax in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...
“VENETOCLAX - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Follicular lymphoma in 7 Major Markets. A detailed picture of the VENETOCLAX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.